Cases & Deals

  • Home
  • Practices
  • Amolyt Pharma enters into definitive agreement to be acquired by AstraZeneca

Share

Amolyt Pharma enters into definitive agreement to be acquired by AstraZeneca

March 2024

Client(s) Amolyt Pharma SAS

Jones Day is advising Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.